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Introduction and rationale
Cognitive impairment in multiple sclerosis reduces patients’ 
life satisfaction and health-related quality of life. It is prob-
ably the most important determinant of employment status 
and associated societal costs, and also adversely affects 
driving safety, household task completion, social activity, 
physical independence, rehabilitation progress, coping, 
treatment adherence and mental health.1 There is a high 
functional impact on young adults in demanding environ-
ments. Reported cognitive impairment prevalence rates are 
between 43% and 70%. They occur in all disease stages, 
including clinically isolated syndrome (CIS) and early 
relapsing–remitting MS (RRMS). Cognition is only loosely 
related to disease duration2 and physical disability (in some 
instances clearly dissociated)3 and is more strongly related 
to brain MRI parameters, especially atrophy.4
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Abstract
Background: Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. 
Full clinical cognitive assessment is expensive, requiring expert staff and special equipment. Test versions and normative 
data are not available for all languages and cultures. 
Objective: To recommend a brief cognitive assessment for multiple sclerosis (MS) that is optimized for small centers, with 
one or few staff members, who may not have neuropsychological training and constructed to maximize international use.
Methods: An expert committee of twelve members representing the main cultural groups that have so far contributed 
considerable data about MS cognitive dysfunction was convened. Following exhaustive literature review, peer-reviewed 
articles were selected to cover a broad spectrum of cultures and scales that targeted cognitive domains vulnerable to MS. 
Each was rated by two committee members and candidates scales were rated on psychometric qualities (reliability, validity, and 
sensitivity),  international application, ease of administration, feasibility in the specified context, and acceptability to patients. 
Results: The committee recommended the Symbol Digit Modalities Test, if only 5 minutes was available, with the addition 
of the California Verbal Learning Test – Second Edition and the Brief Visuospatial Memory Test – Revised learning trials if 
a further 10 minutes could be allocated for testing. 
Conclusions: A brief cognitive assessment for MS has been recommended. A validation protocol has been prepared for 
language groups and validation studies have commenced.
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Cognitive deficits typically involve a few cognitive 
domains, spare language and are often undetected at con-
sultation.5 Information processing speed is the most vulner-
able cognitive ability, followed by episodic memory, and 
executive function.6 Deficits may be mild. There is high 
interpatient variability, in part due to varying compensation 
capacities (cognitive reserve).7 Patients may not be fully 
aware of their deficits, or may not report them reliably: 
depression results in over-reporting,8 whilst metamemory 
impairment and insight loss lead to underestimation in up 
to a third.9 MS cognitive deficits occur in the context of 
sensory and motor impairments10 and reduced functioning 
and engagement is easily attributable to physical disabili-
ties. Cognitive impairment is not always at the forefront of 
the neurologist’s mind, although cognitive decline could be 
as important to the patient as physical relapses or MRI 
lesions.11
Addressing cognitive dysfunction is recognised as a 
quality indicator in MS care.12 However, psychometric 
assessment of cognitive status requires time-consuming 
expert evaluation with specialist materials. The most 
 commonly utilised batteries of neuropsychological tests 
validated in MS are the 45-min Brief Repeatable Battery of 
Neuropsychological tests (BRB-N)13 and the 90-min 
Minimal Assessment of Cognitive Function in MS 
(MACFIMS).10 Comprehensive clinical cognitive assess-
ment requires additional expertise in test selection, admin-
istration and interpretation. This is not routinely available 
outside specialist centres.10 Non-specialist cognitive evalu-
ation tools are unsatisfactory. The Expanded Disability 
Status Scale offers only a rudimentary estimate of cognitive 
function.14 Widely used screening instruments, such as the 
Mini Mental State Examination, are insensitive to the MS 
cognitive footprint.15 All of the above considerations point 
to a clear need for a short, well-validated and widely 
accepted tool, which captures the cognitive performance of 
MS patients, and can be used in everyday practice by clini-
cal neurologists or administered by local healthcare 
workers.16
Objective
Our objective was to recommend a clinical tool for neurol-
ogists and healthcare professionals working with people 
with MS, which was not designed to be either a cognitive 
screen or full assessment, but rather a brief monitoring 
instrument. It would be optimised for centres where neu-
ropsychologists are not available. Identifying a brief meas-
urement tool with adequate reliability, validity, sensitivity 
and specificity would allow for more widespread, accurate 
cognitive evaluations. A validated record of cognitive dis-
ability incorporated into routine clinical practise would be 
beneficial. Baseline ratings and regular follow-up assess-
ments would optimise patient management. Data from this 
cognitive monitoring tool could assist therapeutic decision 
making, including determining how best to support patients’ 
involvement in disease management. Information and 
counselling could be offered, facilitating adjustment at 
work and home. The effect of a start or shift in Disease 
Modifying Drug (DMD) treatment on cognition could be 
monitored, and also the use of cognition enhancers (pro-
vided that sufficient evidence of efficacy is achieved).17 
The brief cognitive tool could also be integrated into more 
detailed, specialist cognitive assessments and used to indi-
cate which patients require expert evaluation, targeting this 
resource more efficiently and equitably. From a global per-
spective, there are currently no cognitive measures for MS 
that are internationally validated and standardised, which is 
a challenge for international study design.
Methods
A committee of seven neurologists and five neuropsycholo-
gists was convened, selected for their expertise in research 
and clinical aspects of MS cognition, and to represent the 
language groups who had so far contributed most signifi-
cantly to the MS cognition literature. There were two co-
chairs (one European, one American). A list of 80 scientific 
articles from peer review journals (http://msj.sagepub.com/
content/early/recent) was assembled after a MEDLINE 
search in June 2010 by the co-chairs (D.L. and R.B.). These 
were chosen to represent a broad international spectrum of 
cognitive scales and their psychometric properties, includ-
ing recent key review articles to allow the committee to 
identify any omissions. The full list was circulated to the 
committee and members were invited to suggest amend-
ments and additions. Prior to the consensus meeting, a sub-
set of articles was circulated to each committee member 
with standardised rating scales for completion. No member 
reviewed an article on which they were an author. Each 
article was rated independently by two committee members 
on three psychometric standards (reliability, validity and 
sensitivity) and four pragmatic standards (international 
applicability, ease of administration, feasibility in the speci-
fied context and acceptability to patients). All ratings were 
3–1 (3 = excellent, 2 = satisfactory, 1 = unsatisfactory). The 
mean rating for each scale and each standard were calcu-
lated, and then the mean overall rating (MOR) for psycho-
metric and pragmatic qualities separately. Raters were also 
invited to submit qualitative comments and judgements. 
Ratings and comments were collated for each candidate 
measure, and all collated ratings, from individual to mean 
scores, were presented to the committee and fully discussed.
Consensus criteria
To meet the specified objectives of the cognitive monitor-
ing tool, it was decided that the recommended battery 
should be completed in 15 min and not require any special 
equipment (beyond papers, pen and stop watch) or specific 
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assessor training. The battery should be easily performed in 
a clinical setting. Discussions at the consensus meeting led 
to agreement that the domains of information processing 
speed, verbal memory and visual memory could be 
included. Executive function scales were felt to be too long 
and too challenging to administer in the target context. It 
was acknowledged that a wide variety of cognitive presen-
tations can be seen clinically,18 but it was felt that a battery 
of scales addressing the three domains identified would 
capture a reasonable proportion of significant cognitive 
impairment in large clinical samples.
Recommended monitoring tests
Information processing speed. There are two widely used 
tests of attention and processing speed in multiple sclero-
sis: the Paced Auditory Serial Addition Task (PASAT)13 
and the Symbol Digit Modalities Test (SDMT, oral form).19 
Both are included in the BRB-N and the MACFIMS. The 
SDMT achieved higher ratings, with a psychometric MOR 
of 2.8 and a pragmatic MOR of 3.0. In comparison, the 
PASAT achieved a psychometric MOR of 2.6 and a prag-
matic MOR of 1.9. Discussion acknowledged that the 
SDMT is more congenial for both patient and assessor, 
takes less time to complete, requires less expertise and 
experience of the assessor and unlike the PASAT, does not 
require special equipment for auditory presentation of 
stimuli. It has equal psychometric validity to the PASAT.20 
The committee considered the evidence that the PASAT has 
detected therapeutic efficacy of disease modifying medica-
tion on cognition,21,22 but felt that the SDMT was the better 
choice for the specified context on feasibility grounds.
The SDMT19 was recommended as the test of informa-
tion processing speed. The test consists of single digits 
paired with abstract symbols (Figure 1). Rows of the nine 
symbols are arranged pseudo-randomly. The patient must 
say the number that corresponds with each symbol. The 
SDMT can be completed within 5 min, including instruc-
tions, practice and testing. The good psychometric proper-
ties of the SDMT are well described.23 The SDMT has a 
reported sensitivity of 82% and a specificity of 60%.24 It 
has validations in several countries.2,24–26 Estimates of prac-
tice effects and change indices are available.27 The SDMT 
has a high sensitivity to cognitive impairment in MS.6,26,28 
It has been shown to be the best predictor of MS cognitive 
impairment in both the BRB-N and MACFIMS.6 The 
SDMT is reliable when administered by nursing staff over 
several months, with minimal practice effects (0.2).29 There 
is also evidence for the sensitivity of the SDMT to cogni-
tive change in MS.2,25,30 The SDMT is well validated 
against both conventional brain MRI parameters (including 
atrophy,31 brain parenchymal fraction (BPF) and third 
 ventricular width,32 atrophy at baseline predicting SDMT 
change;33 cortical lesion number and white matter lesion 
volume,34 cortical lesion volume,32,34.35 cortical lesion 
volume change correlating with SDMT change,36 correla-
tion with some deep grey matter (DGM) nuclei,37 including 
thalamic fraction;32 and fMRI (fractional anisotropy).38 The 
SDMT has also been shown to have external clinical valid-
ity, being significantly linked to both current39 and future30 
employment status.
Verbal memory (immediate recall). Again two candidate 
scales emerged: The California Verbal Learning Test-II 
(CVLT-II)40 and the Selective Reminding Test (SRT).13 The 
CVLT-II is in the MACFIMS and the SRT is in the BRB-N. 
The CVLT-II achieved a psychometric MOR of 2.9 and a 
pragmatic MOR of 2.6. In contrast, the SRT achieved a psy-
chometric MOR of 2.5 and a pragmatic MOR of 2.2. It was 
noted that the SRT format required more expertise in admin-
istration and scoring, compared to the simple list recall for-
mat of the CVLT-II. The committee decided that the first five 
recall trials of the CVLT-II (CVLT-II T1-5) had sufficient 
psychometric rigour, in particular sensitivity to MS impair-
ment,41,42 to be suitable for inclusion in BICAMS. CVLT-II 
T1-5 has been previously recommended as part of a brief MS 
cognitive assessment.43 The first five recall trials have a high 
degree of interdependence to other sections of the CVLT-
II.42 Although this renders conclusions from the validity data 
‡ § ¤ ¬ ¦ Ħ ┌ Ξ ∫
1 2 3 4 5 6 7 8 9
∫ ¤ ¬ ∫ ‡ § ¬ Ħ ∫ § ¬ ∫ § ∫ ¬
Ħ § ∫ ¬ ¤ § ‡ Ħ ∫ ¬ § Ξ Ħ ‡ ┌
Ħ ¤ ¦ ┌ ∫ ‡ ¦ Ħ ┌ ¤ ¬ Ξ ‡ Ħ ¦
¬ Ħ ¤ ∫ § Ħ ∫ ¤ § ¦ Ξ ┌ ‡ § Ħ
Ξ ¤ ┌ ‡ § ¦ Ħ ¤ ¬ ‡ ¦ Ξ ¬ ┌ ∫
§ Ξ ¦ ¬ ‡ § Ħ Ξ ∫ ¦ ¬ ¤ § ┌ Ħ
¬ ┌ ¦ Ξ ‡ ¦ ┌ ¤ ∫ Ξ ¬ ∫ Ħ ‡ §
Figure 1. Example of stimuli of the SDMT type.
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based on the full CVLT-II inferential, it also reduces the 
range of cognitive processes involved.41 The recommenda-
tion carries the pragmatic advantage of reduced administra-
tion time (and possible patient fatigue effects), and a lesser 
requirement for assessor expertise and experience compared 
to the full CVLT-II, which suit our target context.
The recommended verbal memory scale is the CVLT-II 
T1-5.40 This comprises a 16-item word list, with four items 
belonging to each of four categories, arranged randomly 
(Figure 2). The list is read aloud five times in the same order 
to the patient, at a slightly slower rate than one item per sec-
ond. Patients are required to recall as many items as possi-
ble, in any order, after each reading of the list. The CVLT-II 
T1-5 can be completed in 5–10 min, including instructions, 
testing and responses. The CVLT-II T1-5 has been validated 
with brain MR total lesion area and right superior frontal 
atrophy,44 MR T1 and FLAIR lesion volume, BPF and third 
ventricular width32 and MR diffusion measures.42 The full 
CVLT-II has been validated against brain MRI parameters 
(cortical lesion number;34 correlation with some DGM nuclei 
volume,37 including thalamic fraction).32 The full CVLT-II 
also has external clinical validity, in differentiating employed 
MS patients from patients not employed due to MS.41
Visual Memory (immediate recall). Once again, two major 
candidate scales emerged: the Brief Visuospatial Memory 
Test Revised (BVMT-R)45 and the 10/36 Spatial Recall 
Test.13 The BVMT-R is in the MACFIMS and the 10/36 is 
in the BRB-N. The BVMT-R achieved a psychometric 
MOR of 3.0 and a pragmatic MOR of 2.2. In comparison, 
the 10/36 achieved a psychometric MOR of 2.3 and a 
pragmatic MOR of 2.6. The committee’s discussion high-
lighted the reliability of the BVMT-R, the special equip-
ment needed for the 10/36 and the possible ceiling effect 
on the 10/36.7,28 As in the deliberations about the verbal 
memory scale, the conclusion was reached that the first 
three recall trials of the BVMT-R (BVMTR T1-3) would 
be the scale recommended for BICAMS, with similar 
advantages and caveats to those stated above in connec-
tion with the CVLT-II T1-5.
The BVMT-R T1-345 is recommended. The BVMT-R 
T1-3 requires the patient to inspect a 2 × 3 stimulus array of 
abstract geometric figures (Figure 3). There are three learn-
ing trials of 10 s. The array is removed and the patient is 
required to draw the array from memory, with the correct 
shapes in the correct position. The psychometric properties 
of the BVMT-R T1-3 are good.45 Validity of the BVMT-R 
T1-3 has been indicated by significant association with 
brain MR total lesion area,44 T1 lesion and FLAIR lesion 
volume, BPF and third ventricular width32 and right 
Apple
Bear
Piano
Hammer
Banana
Chisel
Trumpet
Orange
Lion
Wrench
Peach
Saw
Drum
Tiger
Violin
Giraffe
Figure 2. Example stimuli of the CVLT-II type.
Figure 3. Example test stimuli of the BVMT-R type.
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superior frontal atrophy44 and correlation with some DGM 
nuclei,37 including thalamic fraction.32
Implementation
For those health professionals with little experience of cog-
nitive assessment, prior review of instructions and practice 
is recommended. Testing should take place in a quiet room, 
with just the patient and the assessor present. The purpose 
of BICAMS should be explained to the patient and if appro-
priate, some background information explaining cognitive 
difficulties in MS should have been made available to the 
patient in advance (e.g. www.stayingsmart.org.uk). It is 
recommended that BICAMS should not be used within 1 
month of recovery from relapse (or if used, the data should 
not be interpreted as indicating long-term decline),46 or 
within 1 month of steroid therapy, which has a proven 
reversible detrimental effect on memory function.47 The 
recommended order of administration is first the SDMT, 
then if time allows the CVLT-II T1-5 and BVMT-R T1-3. In 
most clinical situations, yearly or bi-annual BICAMS eval-
uations will be appropriate.
Confounds and limitations
BICAMS is not intended to replace a full neuropsychologi-
cal assessment, which provides important additional insights 
to the patient, family, and clinician. These more detailed 
evaluations are necessary for in depth rehabilitation and 
vocational counselling and disability determination.
Neuropsychological test performance, including measures 
such as the SDMT, CVLT-II, and BVMT-R, is influenced by 
MS physical symptoms, demographic factors, the presence of 
concurrent neurological disorders other than MS, some con-
current medications, and to a modest degree depression.
Physical symptoms of MS. Whilst the BICAMS component 
scales have been selected to minimise the impact of physical 
impairments on cognitive test performance,10,13 the assessor 
should remain aware of confounds from MS symptoms. For 
example, dysarthria reduces performance on tests requiring 
a spoken response, especially if timed.48 Even mild MS 
visual impairments can also affect cognitive tests with visual 
stimuli.49 The experienced clinician can infer how a patient’s 
physical difficulties prejudice their test scores. Aside from 
the sensory and motor interface with the test situation, there 
are a number of physical symptoms of MS that can interfere 
with cognitive test performance, notably pain.10
Demographic factors. Demographic factors (age, educa-
tion, and gender) affect cognitive performance. Many tests 
have normative data taking account of these variables.50,51 
It is also well established that pre-morbid optimal level will 
affect how far current deterioration is detectable (cognitive 
reserve).7 Some countries have reading scales that estimate 
pre-morbid level.10 If testing materials are not available in 
the patient’s native language, particularly with respect to 
verbal learning and memory, published normative data can-
not be used with any precision to evaluate the patient’s per-
formance. The limited value of BICAMS for patients who 
are not native speakers is as a baseline against which to 
measure future change.
Concurrent neurological/medical disorders. If an MS patient 
has cognitive dysfunction, consideration must be give to 
whether other co-morbid neurological or medical conditions 
exist. In the context of learning disability, most mainstream 
intellectual assessments are inappropriate. It is helpful to ask 
whether or not a diagnosis of learning difficulty or attention 
deficit disorder was present prior to the MS diagnosis, or 
their characteristic features, since these conditions may have 
been present without formally diagnosis. Questions regard-
ing difficulties in school performance or with reading can 
yield helpful information. The medical history should include 
questions regarding past head trauma, cerebrovascular dis-
ease, and other medical conditions such as sleep apnoea.
Concurrent medications. Certain medications commonly 
used in MS can adversely affect cognitive functioning.52 
Benzodiazepines can interfere with vigilance and mem-
ory.53 For many patients high doses of anti-spasticity agents 
such as baclofen are associated with cognitive impair-
ments.54 Anticonvulsants are also known to reduce cogni-
tive function.55 Antidepressant medication can cause 
cognitive inefficiency to varying degrees.52 Cannabis, 
whether prescribed or self-medicated, can influence cogni-
tion.56 It is also important to be alert to other non-prescribed 
medication. Recent changes in cognition should be consid-
ered in the context of any concurrent medication changes.
Depression. Depression is highly prevalent in MS and may 
have mild effects on cognitive functioning, possibly medi-
ated by coping styles.57 It is likely that severe depression 
could interfere with either willingness to undergo testing or 
ability to concentrate. An important aspect of depression’s 
influence on the clinical management of cognition, is that 
depression affects self-report of cognitive problems. 
Patients’ self-report of cognitive impairment does not reli-
ably correlate with their performance at objective cognitive 
testing; in contrast, the relative’s report of the patient’s cog-
nitive status does correlate with the patient’s performance at 
objective cognitive testing.58 Treatment of depression (and 
fatigue) improves patients’ self report of cognitive function, 
but not their objective cognitive test performance.8
Fatigue. Over 80% of MS patients experience fatigue and 
also have the impression that this symptom interferes with 
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their cognitive functions.59 This association has not been 
consistently confirmed in studies of objective cognitive test 
performance. However, it is known that heat, infections, 
pain and depression can increase fatigue and these contrib-
utory factors should be managed to ensure optimum cogni-
tive performance. When feasible, patients should be 
allowed to rest after arriving, before their cognitive assess-
ment, to minimise the effects of fatigue.60 Those undergo-
ing repeated testing should if possible be evaluated at the 
same time of day as the original assessment, to avoid vari-
ance from time of day fatigue effects.
Future work and development of 
BICAMS
An international validation protocol for BICAMS is under 
development. Several national validation and standardisation 
projects are under way. It is envisaged that over time, many 
nations will be able to utilise BICAMS as part of routine 
clinical MS practice, referring to appropriate national norms. 
International MS natural history studies and treatment trials 
with cognition outcomes will be assisted by an internation-
ally standardised battery. In order to support this process and 
facilitate access to materials and norms, the BICAMS com-
mittee is working to publish BICAMS updates in scientific 
and professional journals and meetings. The BICAMS web-
site (www.BICAMS.net) will be a focus for this process, 
with a commitment to open access whenever possible.
Summary
An expert consensus committee of neurologists and neu-
ropsychologists, with extensive research and clinical expe-
rience of MS cognition, have recommended a Brief 
International Assessment of Cognition for MS (BICAMS).16 
The battery takes 15 min to complete, requires no specialist 
equipment and no specialist expertise in cognitive assess-
ment. BICAMS comprises:
•	 The Symbol Digit Modalities Test
•	 The California Verbal Learning Test –II, first five 
recall trials
•	 The Brief Visuospatial Memory Test –Revised, first 
three recall trials.
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